GALT: Galectin Therapeutics, Inc. Narx/daromad multiplikatori

Galectin Therapeutics (GALT) kompaniyasining strategik maqsadi dori vositalarini ishlab chiqishda etik ESG standartlarini joriy etishdan iboratdir. GURU.Markets terminalining analitik grafigidagi daromad multiplikatori dinamikasi ushbu maqsad sari yo'lni vizuallashtiradi, bunda darajasi joriy miqdorni aks ettiradi. Biroq, sirrozda belapectin uchun klinik sinovlar xavflari hamda jigar fibrozi va NASH uchun tasdiqlangan terapiyalarning yetishmasligi sezilarli to'siqlar bo'lib qolmoqda.

Narxning daromadga nisbati: Galectin Therapeutics Inc. (GALT) 04.07.2022 - 13.11.2026 uchun

Galectin Therapeutics (GALT) kompaniyasining tahliliy kesimlari

- aksiya narxi va baholash bo'yicha konsensus prognoz:

Narxlar dinamikasi grafigi galectintherapeutics.com|GALT - Tahlilchilar konsensus prognozi

- bozor kapitallashuvi haqida ma'lumot:

Bozor kapitallashuvi Galectin|GALT - Korxona qiymati

- balans kapitallashuvi bo'yicha ma'lumotlar:

Bitta aksiya hisobiga balans qiymati Galectin Therapeutics|GALT - Kompaniyaning balans qiymati|Bozor qiymatining balans qiymatiga nisbati galectintherapeutics.com|GALT - Kompaniyaning umumiy aktivlari

- qarz majburiyatlari va likvidlik statistikasi:

Qarzning kapitalga nisbati Galectin Therapeutics|GALT - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati galectintherapeutics.com|GALT - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati Galectin|GALT - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi Galectin Therapeutics|Shoshilinch likvidlik koeffitsiyenti galectintherapeutics.com

- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:

GALT - Sof daromad|Kutilayotgan sof daromad Galectin Therapeutics|GALT - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati galectintherapeutics.com|GALT - PEG multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Galectin|GALT - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Galectin Therapeutics|GALT - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi galectintherapeutics.com|GALT - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Galectin Therapeutics

- umumiy tushum va sotuv hajmi ma'lumotlari:

GALT - Kompaniya daromadi|Kompaniyaning kutilayotgan daromadi galectintherapeutics.com|GALT - P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Galectin

Kompaniyaning jamlanma tahliliyoti:Galectin Therapeutics, Inc.

Galectin Therapeutics Inc. seriyali mahsuloti

Galectin Therapeutics (GALT) investori uchun model barqarorligini baholash, monoklonal antitelar patentlari va FDA tasdig'i uchun ketayotgan shiddatli poyga sharoitida bozor kapitalizatsiyasi haqiqiy daromadlar bilan qanchalik asoslanganligiga bog'liq. P/S koeffitsiyenti tendentsiyasini tahlil qilishda, ushbu metrika joriy biznes qiymatini savdo hajmi bilan bog'lashini tushunish muhimdir, bu esa aktivlarning haddan tashqari qimmat baholanganini yoki stagnatsiya holatidagi korxonaga investitsiya kiritish xavfini aniqlash imkonini beradi.

Raqobatdosh kompaniyalar

ARWR (arrowheadpharma.com) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori MIRM (Mirum)|Narx/daromad multiplikatori Dynavax Corp|Arbutus - P/S multiplikatori|IVA - P/S multiplikatori|Gyre Therapeutics, Inc. (GYRE) - Narxning daromadga nisbati|ASMB (assemblybio.com) - Narxning daromadga nisbati|GNFT (Genfit SA) - P/S multiplikatori|Sotuvga nisbatan narx DURECT Corp. DRRX|P/S multiplikatori ALGS|Kapitalizatsiyaning daromadga nisbati biovieinc.com BIVI|Galmed Pharmaceuticals Ltd. - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati NDRA (endrainc.com)|Hepion Pharma - P/S multiplikatori